New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming

doi:10.3760/cma.j.issn.1673-422X.2019.07.012

Abstract

Abstract: For the last decade, the incidence of kidney neoplasms has shown an obvious rising trend in the world. The most common histopathological type of kidney neoplasms is clear cell renal cell carcinoma (ccRCC), which has a poor prognosis. ccRCC is generally accompanied by reprogramming of glucose, fatty acid, glutamine, tryptophan and arginine metabolic networks and pathways. Reprogramming of metabolic networks and pathways enables tumor cells to proliferate rapidly, survive in conditions of nutrient depletion and hypoxia, and escape surveillance by epidemic systems. New strategies have been developed to the treatment of ccRCC by targeting key proteins or enzymes involved in metabolic reprogramming pathways.

Key words: Kidney neoplasms, Metabolic networks and pathways, Therapy

Chen Liang, Peng Min, Weng Yiming, Song Qibin. New strategies for the treatment of clear cell renal cell carcinoma: target the metabolic reprogramming[J]. Journal of International Oncology, 2019, 46(7): 443-446.

References

［1］ Sciacovelli M, Frezza C. Metabolic reprogramming and epithelialtomesenchymal transition in cancer［J］. FEBS J, 2017, 284(19): 31323144. DOI: 10.1111/febs.14090. ［2］ Hakimi AA, Reznik E, Lee CH, et al. An integrated metabolic atlas of clear cell renal cell carcinoma［J］. Cancer Cell, 2016, 29(1): 104116. DOI: 10.1016/j.ccell.2015.12.004. ［3］ Lameirinhas A, MirandaGonalves V, Henrique R, et al. The complex interplay between metabolic reprogramming and epigenetic alterations in renal cell carcinoma［J］. Genes (Basel), 2019, 10(4). pii: E264. DOI: 10.3390/genes10040264. ［4］ Tarade D, Ohh M. The HIF and other quandaries in VHL disease［J］. Oncogene, 2018, 37(2): 139147. DOI: 10.1038/onc.2017.338. ［5］ Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers［J］. J Clin Invest, 2019, 129(2): 442451. DOI: 10.1172/JCI120855. ［6］ Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma［J］. Nature, 2013, 499(7456): 4349. DOI: 10.1038/nature12222. ［7］ Wettersten HI, Hakimi AA, Morin D, et al. Gradedependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis［J］. Cancer Res, 2015, 75(12): 25412552. DOI: 10.1158/00085472.CAN141703. ［8］ Crooks DR, Linehan WM. The Warburg effect in hominis: isotoperesolved metabolism in ccRCC［J］. Nat Rev Urol, 2018, 15(12): 731732. DOI: 10.1038/s4158501801101. ［9］ Ambrosetti D, Dufies M, Dadone B, et al. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clearcell renal cell carcinoma［J］. PLoS One, 2018, 13(2): e0193477. DOI: 10.1371/journal.pone.0193477. ［10］ Courtney KD, Bezwada D, Mashimo T, et al. Isotope tracing of human clear cell renal cell carcinomas demonstrates suppressed glucose oxidation in vivo［J］. Cell Metab, 2018, 28(5): 793800.e2. DOI: 10.1016/j.cmet.2018.07.020. ［11］ Dong B, Gao Y, Kang X, et al. SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis［J］. Oncotarget, 2016, 7(49): 8043580449. DOI: 10.18632/oncotarget.12606. ［12］ Gameiro PA, Yang, Metelo AM, et al. In vivo HIFmediated reductive carboxylation is regulated by citrate levels and sensitizes VHLdeficient cells to glutamine deprivation［J］. Cell Metab, 2013, 17(3): 372385. DOI: 10.1016/j.cmet.2013.02.002. ［13］ Shu X, Gu J, Huang M, et al. Germline genetic variants in somatically significantly mutated genes in tumors are associated with renal cell carcinoma risk and outcome［J］. Carcinogenesis, 2018, 39(6): 752757. DOI: 10.1093/carcin/bgy021. ［14］ Schdel J, Grampp S, Maher ER, et al. Hypoxia, hypoxiainducible transcription factors, and renal cancer［J］. Eur Urol, 2016, 69(4): 646657. DOI: 10.1016/j.eururo.2015.08.007. ［15］ Miikkulainen P, Hgel H, Seyednasrollah F, et al. Hypoxiainducible factor (HIF)prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma［J］. J Biol Chem, 2019, 294(10): 37603771. DOI: 10.1074/jbc.RA118.004902. ［16］ Scheuermann TH, Li Q, Ma HW, et al. Allosteric inhibition of hypoxia inducible factor2 with small molecules［J］. Nat Chem Biol, 2013, 9(4): 271276. DOI: 10.1038/nchembio.1185. ［17］ Cho H, Du X, Rizzi JP, et al. Ontarget efficacy of a HIF2α antagonist in preclinical kidney cancer models［J］. Nature, 2016, 539(7627): 107111. DOI: 10.1038/nature19795. ［18］ Chen W, Hill H, Christie A, et al. Targeting renal cell carcinoma with a HIF2 antagonist［J］. Nature, 2016, 539(7627): 112117. DOI: 10.1038/nature19796. ［19］ Wallace EM, Rizzi JP, Han G, et al. A smallmolecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma［J］. Cancer Res, 2016, 76(18): 54915500. DOI: 10.1158/00085472.CAN160473. ［20］ Peloton Therapeutics, Inc. A phase 1, doseescalation trial of PT2385 tablets in patients with advanced clear cell renal cell carcinoma ［EB/OL］. Clinicaltrials.gov. (20181115) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT02293980?term=02293980&rank=1. ［21］ Lucarelli G, Rutigliano M, Sallustio F, et al. Integrated multiomics characterization reveals a distinctive metabolic signature and the role of NDUFA4L2 in promoting angiogenesis, chemoresistance, and mitochondrial dysfunction in clear cell renal cell carcinoma［J］. Aging (Albany NY), 2018, 10(12): 39573985. DOI: 10.18632/aging.101685. ［22］ Abu Aboud O, Donohoe D, Bultman S, et al. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth［J］. Am J Physiol Cell Physiol, 2015, 308(11): C890C898. DOI: 10.1152/ajpcell.00322.2014. ［23］ Shroff EH, Eberlin LS, Dang VM, et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism［J］. Proc Natl Acad Sci U S A, 2015, 112(21): 65396544. DOI: 10.1073/pnas.1507228112. ［24］ Abu Aboud O, Habib SL, Trott J, et al. Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for realtime imaging［J］. Cancer Res, 2017, 77(23): 67466758. DOI: 10.1158/00085472.CAN170930. ［25］ Emberley E, Bennett M, Chen J, et al. CB839, a selective glutaminase inhibitor, has antitumor activity in renal cell carcinoma and synergizes with cabozantinib and everolimus［EB/OL］. Keystone Symposia, Tumor Metabolism: Mechanisms and Targets, Whistler Canada. 2017. ［20190401］. https://www.calithera.com/wpcontent/uploads/2017/12/03.2017KeystoneposterEmberley2017.pdf. ［26］ Hoerner CR, Chen VJ, Fan AC. The ‘Achilles Heel’ of metabolism in renal cell carcinoma: glutaminase inhibition as a rational treatment strategy［J］. Kidney Cancer, 2019, 3(1): 1529. DOI: 10.3233/KCA180043. ［27］ Calithera Biosciences, Inc. Phase 2 study comparing CB839 in combination with everolimus (CBE) vs. placebo with everolimus (PboE) in patients with advanced or metastatic RCC［EB/OL］. Clinical trials.gov. (20190215) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT03163667?term=03163667&rank=1. ［28］ Sadok I, Gamian A, Staniszewska MM. Chromatographic analysis of tryptophan metabolites［J］. J Sep Sci, 2017, 40(15): 30203045. DOI: 10.1002/jssc.201700184. ［29］ Lucarelli G, Rutigliano M, Ferro M, et al. Activation of the kynurenine pathway predicts poor outcome in patients with clear cell renal cell carcinoma［J］. Urol Oncol, 2017, 35(7): 461.e15461.e27. DOI: 10.1016/j.urolonc.2017.02.011. ［30］ Mondanelli G, Bianchi R, Pallotta MT, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells［J］. Immunity, 2017, 46(2): 233244. DOI: 10.1016/j.immuni.2017.01.005. ［31］ Amobi A, Qian F, Lugade AA, et al. Tryptophan catabolism and cancer immunotherapy targeting IDO mediated immune suppression［J］. Adv Exp Med Biol, 2017, 1036: 129144. DOI: 10.1007/9783319675770_9. ［32］ Trott JF, Kim J, Abu Aboud O, et al. Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer［J］. Oncotarget, 2016, 7(41): 6654066557. DOI: 10.18632/oncotarget.11658. ［33］ Jochems C, Fantini M, Fernando RI, et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigenspecific T cells［J］. Oncotarget, 2016, 7(25): 3776237772. DOI: 10.18632/oncotarget.9326. ［34］ Sheridan C. IDO inhibitors move center stage in immunooncology［J］. Nat Biotechnol, 2015, 33(4): 321322. DOI: 10.1038/nbt0415321. ［35］ NayakKapoor A, Hao Z, Sadek R, et al. Phase Ia study of the indoleamine 2,3dioxygenase 1 (IDO1) inhibitor navoximod (GDC0919) in patients with recurrent advanced solid tumors［J］. J Immunother Cancer, 2018, 6(1): 61. DOI: 10.1186/s4042501803519. ［36］ Incyte Corporation. A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO203)［EB/OL］. Clinical trials.gov. (20190410) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT02318277?term=02318277&rank=1. ［37］ Jahani M, Noroznezhad F, Mansouri K. Arginine: challenges and opportunities of this twofaced molecule in cancer therapy［J］. Biomed Pharmacother, 2018, 102: 594601. DOI: 10.1016/j.biopha.2018.02.109. ［38］ Ochocki JD, Khare S, Hess M, et al. Arginase 2 suppresses renal carcinoma progression via biosynthetic cofactor pyridoxal phosphate depletion and increased polyamine toxicity［J］. Cell Metab, 2018, 27(6): 12631280.e6. DOI: 10.1016/j.cmet.2018.04.009. ［39］ Burrows N, Cane G, Robson M, et al. Hypoxiainduced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADIPEG20)［J］. Sci Rep, 2016, 6: 22950. DOI: 10.1038/srep22950. ［40］ Kremer JC, Prudner BC, Lange SES, et al. Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1deficient cancers［J］. Cell Rep, 2017, 18(4): 9911004. DOI: 10.1016/j.celrep.2016.12.077. ［41］ Polaris Group. Study ADIPEG 20 plus pembrolizumab in advanced solid cancers［EB/OL］. Clinical trials.gov. (20180222) ［20190401］. https://www.clinicaltrials.gov/ct2/show/NCT03254732?term=03254732&rank=1.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[4]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[5]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[6]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[7]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[8]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan. Progress of ferroptosis-related mechanisms in osteosarcoma [J]. Journal of International Oncology, 2024, 51(5): 308-311.
[9]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[10]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[11]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[12]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[13]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[14]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[15]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.